Can-Fite BioPharma Projects $685 Million in Future Revenue via Collaborations
The company said it currently has seven partnerships, one of the biggest with EwoPharma, with a potential revenue of about
The company said it also expects "substantial" revenue over the next decade from its lead drug candidates, Piclidenoson and Namodenoson. These drugs are in development for psoriasis, advanced liver cancer, pancreatic cancer, and metabolic dysfunction-associated steatohepatitis, or MASH.
Price: 1.60, Change: +0.02, Percent Change: +1.59
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
© 1999-2025 Midnight Trader, Inc. All rights reserved.
close
Can-Fite BioPharma Projects $685 Million in Future Revenue via Collaborations
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "
Your e-mail has been sent.
close
Your e-mail has been sent.
Related News
-
Trade tensions are giving Intel's older chips a second life
Reuters - 20 minutes ago
-
Trade tensions are giving Intel's older chips a second life
Reuters - 25 minutes ago
-
IMF focused on stability but will support countries on climate risks, Georgieva says
Reuters - 28 minutes ago
-
Harvard University exploring $1 billion of private equity stakes sale, source says
Reuters - 42 minutes ago
-
US prosecutors to seek death penalty against Luigi Mangione in UnitedHealth executive's murder
Reuters - 49 minutes ago
-
Analysis-After years of failed AI deals, Intel plans homegrown challenge to Nvidia
Reuters - 52 minutes ago
-
Prosecutors file formal notice of plan to seek death penalty for Luigi Mangione
Reuters - 8:06 PM ET 4/24/2025
Content for this page, unless otherwise indicated with a Fidelity pyramid logo, is selected and published by Fidelity Interactive Content Services LLC ("FICS"), a Fidelity company. All Web pages published by FICS will contain this legend. FICS was established to present users with objective news, information, data and guidance on personal finance topics drawn from a diverse collection of sources including affiliated and non-affiliated financial services publications. Content selected and published by FICS drawn from affiliated Fidelity companies is labeled as such. FICS-selected content provided is not intended to provide tax, legal, insurance, or investment advice, and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by any Fidelity entity or any third party. Quotes are delayed unless otherwise noted. FICS is owned by FMR LLC and is an affiliate of Fidelity Brokerage Services LLC. Terms of use for Third-Party Content and Research
These links are provided by Fidelity Brokerage Services LLC ("FBS") for educational and informational purposes only. FBS is responsible for the information contained in the links. FICS and FBS are separate but affiliated companies and FICS is not involved in the preparation or selection of these links, nor does it explicitly or implicitly endorse or approve information contained in the links.
Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.
